Perioperative use of NSAIDs and the risk of short-term endoscopic recurrence in Crohn's disease patients: A retrospective cohort study

Am J Surg. 2023 Jun;225(6):1045-1049. doi: 10.1016/j.amjsurg.2022.12.003. Epub 2022 Dec 8.

Abstract

Background: More evidence is needed on the use of NSAID based postoperative pain regimens for Crohn's disease (CD) and its association with recurrence. Our goal is to assess the impact of perioperative use of NSAIDs on endoscopic disease recurrence in patients with CD.

Methods: A retrospective cohort study was conducted. The primary outcome measured was endoscopic disease recurrence within 24 months of surgery, defined as a Rutgeerts score ≥ i2.

Results: We identified 107 patients with CD that underwent index ileocolectomy with primary anastomosis between January 2009 and July 2019. Endoscopic disease recurrence was identified in 28 (26.2%) and clinical recurrence in 18 (16.8%) patients. Exposure to NSAIDs did not increase 24-month endoscopic recurrence risk (22.2% vs. 38.5% patients, p = 0.12).

Conclusion: In patients with CD undergoing elective ileocolic resection and primary ileocolic anastomosis, NSAID use in the perioperative period did not impact endoscopic or clinical disease recurrence rate.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Colectomy / adverse effects
  • Colon / surgery
  • Colonoscopy
  • Crohn Disease* / drug therapy
  • Crohn Disease* / surgery
  • Humans
  • Ileum / surgery
  • Recurrence
  • Retrospective Studies

Substances

  • Anti-Inflammatory Agents, Non-Steroidal